Home/Filings/4/0000899243-24-000108
4//SEC Filing

Havencrest Healthcare Partners, L.P. 4

Accession 0000899243-24-000108

CIK 0001799191other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 8:02 PM ET

Size

14.9 KB

Accession

0000899243-24-000108

Insider Transaction Report

Form 4
Period: 2024-01-19
Transactions
  • Sale

    Common stock

    2024-01-23$2.11/sh5,338$11,26352,413 total(indirect: See footnote)
  • Sale

    Common stock

    2024-01-19$2.13/sh11,986$25,53068,014 total(indirect: See footnote)
  • Sale

    Common stock

    2024-01-22$2.12/sh10,263$21,75857,751 total(indirect: See footnote)
Holdings
  • Common stock

    (indirect: See footnote)
    8,801,823
TOI HC I, LLC
10% Owner
Transactions
  • Sale

    Common stock

    2024-01-19$2.13/sh11,986$25,53068,014 total(indirect: See footnote)
  • Sale

    Common stock

    2024-01-23$2.11/sh5,338$11,26352,413 total(indirect: See footnote)
  • Sale

    Common stock

    2024-01-22$2.12/sh10,263$21,75857,751 total(indirect: See footnote)
Holdings
  • Common stock

    (indirect: See footnote)
    8,801,823
Transactions
  • Sale

    Common stock

    2024-01-23$2.11/sh5,338$11,26352,413 total(indirect: See footnote)
  • Sale

    Common stock

    2024-01-19$2.13/sh11,986$25,53068,014 total(indirect: See footnote)
  • Sale

    Common stock

    2024-01-22$2.12/sh10,263$21,75857,751 total(indirect: See footnote)
Holdings
  • Common stock

    (indirect: See footnote)
    8,801,823
Footnotes (5)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.19, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.08 to $2.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.08 to $2.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  • [F4]Havencrest Healthcare Partners GP, LLC (the "General Partner") is the record holder of these shares of the Issuer's common stock.
  • [F5]TOI HC I, LLC is the record holder of these 8,801,823 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. The General Partner controls Havencrest Healthcare Partners, L.P.

Issuer

Oncology Institute, Inc.

CIK 0001799191

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001705748

Filing Metadata

Form type
4
Filed
Jan 22, 7:00 PM ET
Accepted
Jan 23, 8:02 PM ET
Size
14.9 KB